Relationship between insulin-like growth factor-I and low-density lipoprotein cholesterol levels in primary hypothyroidism in women

1989 ◽  
Vol 123 (2) ◽  
pp. 341-345 ◽  
Author(s):  
N. Hoogerbrugge–v.d.Linden ◽  
H. Jansen ◽  
W. C. Hülsmann ◽  
J. C. Birkenhäger
Keyword(s):  
Growth Factor ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Primary Hypothyroidism ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Igf I

ABSTRACT The effect of insulin-like growth factor-I (IGF-I) on the disturbance of lipid metabolism during primary hypothyroidism was studied in 12 women with primary hypothyroidism. Significant increases in both low-density lipoprotein (LDL) cholesterol and intermediate-density lipoprotein cholesterol were seen. Lipoprotein concentrations reverted to normal after substitution with thyroxine (T4) until the euthyroid state was reached. A decrease in IGF-I of 65% (P<0·005) was seen in hypothyroid patients and this was inversely correlated (r=−0·75; P<0·01) with the concentration of LDL cholesterol. Multivariate regression analysis of LDL cholesterol against IGF-I and free T4 showed that IGF-I determines the concentration of LDL cholesterol instead of free T4. Our data suggest that in hypothyroidism, IGF-I is a determinant of the concentration of LDL cholesterol. In addition, hypothyroidism can influence plasma lipoprotein metabolism by lowering the activity of the salt-resistant lipase (liver lipase). Journal of Endocrinology (1989) 123, 341–345

Insulin-like growth factor-binding protein-1 is correlated with low density lipoprotein cholesterol in normal subjects

1994 ◽  
Vol 140 (3) ◽  
pp. 521-524 ◽  
Author(s):  
K D Hopkins ◽  
E D Lehmann ◽  
J R Parker ◽  
R G Gosling
Keyword(s):  
Body Mass Index ◽  
Growth Factor ◽  
Body Mass ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
The Body ◽  
Low Density ◽  
Insulin Like Growth Factor ◽  
Igf I

Abstract Insulin-like growth factor-I (IGF-I) has been inversely associated with low-density lipoprotein (LDL) cholesterol in normal women with slightly elevated cholesterol levels and hypothyroid women. More than 95% of IGF-I circulates bound to binding proteins (IGFBPs); of these IGFBP-1 is of particular interest as it is inversely regulated by insulin and is thought to inhibit the action of IGF-I and IGF-II. We examined the relationship between IGFBP-1 and LDL cholesterol in 41 healthy adult subjects. LDL cholesterol correlated with the body mass index (r=0·40, P<0·01), sex (r=0·51, P<0·001) and IGFBP-1 levels (r=0·36, P<0·02). LDL cholesterol did not correlate with age (r=0·25, P=not significant) or IGF-I (r=0·06, P=not significant). Upon multivariate regression analysis, sex, body mass index and IGFBP-1 were all independent predictors of LDL cholesterol (all P<0·05). Elevated IGFBP-1 levels have been associated with an inhibition of serum IGF-I bioactivity in children with insulin-dependent diabetes. IGFBP-1 also appears to inhibit IGF-I hexose-stimulated uptake. IGFBP-1 may also be inhibiting the effect of IGFs on the cellular metabolism of LDL cholesterol. Journal of Endocrinology (1994) 140, 521–524

scholarly journals Clinical Significance of Electronegative Low-Density Lipoprotein Cholesterol in Atherothrombosis

Biomedicines ◽  
2020 ◽  
Vol 8 (8) ◽  
pp. 254 ◽  
Author(s):  
Chih-Sheng Chu ◽  
Shi Hui Law ◽  
David Lenzen ◽  
Yong-Hong Tan ◽  
Shih-Feng Weng ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Clinical Significance ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Exercise Stress ◽  
Lipoprotein Cholesterol ◽  
Lipid Lowering ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol

Despite the numerous risk factors for atherosclerotic cardiovascular diseases (ASCVD), cumulative evidence shows that electronegative low-density lipoprotein (L5 LDL) cholesterol is a promising biomarker. Its toxicity may contribute to atherothrombotic events. Notably, plasma L5 LDL levels positively correlate with the increasing severity of cardiovascular diseases. In contrast, traditional markers such as LDL-cholesterol and triglyceride are the therapeutic goals in secondary prevention for ASCVD, but that is controversial in primary prevention for patients with low risk. In this review, we point out the clinical significance and pathophysiological mechanisms of L5 LDL, and the clinical applications of L5 LDL levels in ASCVD can be confidently addressed. Based on the previously defined cut-off value by receiver operating characteristic curve, the acceptable physiological range of L5 concentration is proposed to be below 1.7 mg/dL. When L5 LDL level surpass this threshold, clinically relevant ASCVD might be present, and further exams such as carotid intima-media thickness, pulse wave velocity, exercise stress test, or multidetector computed tomography are required. Notably, the ultimate goal of L5 LDL concentration is lower than 1.7 mg/dL. Instead, with L5 LDL greater than 1.7 mg/dL, lipid-lowering treatment may be required, including statin, ezetimibe or PCSK9 inhibitor, regardless of the low-density lipoprotein cholesterol (LDL-C) level. Since L5 LDL could be a promising biomarker, we propose that a high throughput, clinically feasible methodology is urgently required not only for conducting a prospective, large population study but for developing therapeutics strategies to decrease L5 LDL in the blood.

scholarly journals Validation of the Modified Friedewald’s Formula to Calculate Low-density Lipoprotein Cholesterol in Bangladeshi Population

2012 ◽  
Vol 30 (3) ◽  
pp. 141-144
Author(s):  
Mimi Parvin ◽  
Muhammad Saiedullah ◽  
Aminul Haque Khan ◽  
Muhammad Rezwanur Rahman ◽  
Md Saiful Islam
Keyword(s):  
Correlation Coefficient ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Serum Triglyceride ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Bangladeshi Population ◽  
Modified Formula

Objective: A modification of Friedewald’s formula was proposed to calculate LDL cholesterol in Bangladeshi population up to serum triglyceride concentration of 1000 mg/dL. The aim of this study was to validate the modification of Friedewald’s formula in Bangladeshi population.Methods: Serum total cholesterol, triglyceride, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol concentrations were measured in specimens obtained form 314 adult Bangladeshi subjects selected conveniently. LDL cholesterol concentrations were also calculated by modified Friedewald’s formula and original Friedewald’s formula. Results were expressed as mean ± SD and calculated LDL cholesterol was compared with measured LDL cholesterol by two-tailed paired t test and Pearson’s correlation coefficient (r).Results: The mean ± SD of measured LDL cholesterol was 138.3 ± 54.58 mg/dL. LDL cholesterol calculated by modified Friedewald’s formula and original Friedewald’s formula were 135.9 ± 59.26 mg/dL (P>0.05) and 123.5 ± 65.75 mg/dL (P<0.001) respectively. Compared to measured LDL cholesterol, calculated LDL cholesterol were 2.47 mg/ dL and 17.20 mg/dL lower for modified formula and original formula respectively. The correlation coefficient (r) with measured LDL cholesterol was 0.8601 (P<0.0001) for LDL cholesterol calculated by the modified Friedewald’s formula and 0.8565 (P<0.0001) for the LDL cholesterol calculated by the original Friedewald’s formula.Conclusion: The study validates the modified Friedewald’s formula to calculate LDL cholesterol in Bangladeshi    population. DOI: http://dx.doi.org/10.3329/jbcps.v30i3.12463 J Bangladesh Coll Phys Surg 2012; 30: 141-144

The Insulin-Like Growth Factor, Somatomedin-C, Modulates Low Density Lipoprotein Metabolism by Swine Granulosa Cells*

Endocrinology ◽  
1987 ◽  
Vol 121 (1) ◽  
pp. 340-346 ◽  
Author(s):  
JOHANNES D. VELDHUIS ◽  
JOHN E. NESTLER ◽  
JEROME F. STRAUSS ◽  
PAULA AZIMI ◽  
JAMES GARMEY ◽  
...  
Keyword(s):  
Growth Factor ◽  
Granulosa Cells ◽  
Low Density Lipoprotein ◽  
Lipoprotein Metabolism ◽  
Density Lipoprotein ◽  
Low Density ◽  
Insulin Like Growth Factor ◽  
Somatomedin C
Sign in / Sign up

Export Citation Format

Share Document